Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

I still believe the market is overbought as we now have less than a month until the election, which most of the country wishes was over already. Although I believe the overall market is overvalued -- especially consumer staples and utilities, which are seeing little growth but have been bid up nonetheless by investors desperate for any kind of yield -- there are still some pockets of value within equites.

Among these pockets is the biopharma space; that's provided Democrats do not get a clean sweep this election cycle, which could trigger substantial legislative changes in the industry. I slowly have been adding exposure to this sector recently as I don't believe this overhaul will happen. Here are a couple names I have added to recently and that look significantly undervalued....429 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.